Skip to main content

Table 2 Outcomes tested for an association with global European ancestry in African Americans from EAGLE BioVU

From: Towards a phenome-wide catalog of human clinical traits impacted by genetic ancestry

Outcome (n)

% or mean (± SD)

OR or β (95 % CI or SE)

P-value

Hypertension, baseline (n = 6,422)

56 %

1.20 (0.90 – 1.59)

0.21

Hypertension, lifetime (n = 8,691)

78 %

1.23 (0.82 – 1.86)

0.32

Type 2 diabetes (n = 1,356)

12 %

1.32 (0.91 – 1.91)

0.15

Albumin (g/dL), serum (n = 8,094)

4.05 (0.51)

−0.001 (0.04)

0.88

Albumin creatinine ratio (mg/mmol) (n = 1,210)

14.0 (861.10)

−123.82 (176.60)

0.48

Albumin (mg/dL), urinary (n = 1,199)

16.7 (640.2)

−36.35(131.80)

0.78

Blood urea nitrogen (mg/dL) (n = 10,111)

11.00 (13.55)

−0.23 (0.93)

0.80

Body mass index (kg/m2) (n = 9,247)

27.25 (7.21)

0.74 (0.51)

0.15

Creatinine (mg/dL), serum (n = 10,288)

0.88 (1.99)

0.07 (0.13)

0.59

Creatinine (g/kg/day), urinary (n = 172)

70.00 (73.89)

23.05 (38.86)

0.55

Diastolic blood pressure (mm Hg), baseline (n = 10,025)

76.00 (15.68)

0.48 (1.07)

0.66

Diastolic blood pressure (mm Hg), post-medication (n = 5,653)

79.00 (10.06)

0.29 (0.90)

0.75

Diastolic blood pressure (mm Hg), pre-medication (n = 7,009)

75.00 (11.28)

0.38 (0.92)

0.68

Glucose (mg/dL) (n = 9,918)

96.00 (34.33)

0.04 (2.37)

0.99

Glycated hemoglobin (mg/dL) (n = 2,925)

6.30 (1.80)

0.07 (0.23)

0.75

HDL-C (mg/dL) (n = 5,096)

50.00 (16.99)

−1.02 (1.65)

0.54

HDL-c (mg/dL) post-medication (n = 2,097)

47.75 (16.56)

−2.95 (2.48)

0.23

HDL-C (mg/dL), pre-medication (n = 4,273)

51.00 (17.09)

−0.91 (1.81)

0.61

Heart rate (beats per minute) (n = 783)

76.00 (11.14)

−3.28 (2.67)

0.22

Insulin (IU/mL) (n = 343)

16.90 (74.36)

−11.15 (24.38)

0.65

LDL-C (mg/dL), regardless of medication status

99.00 (35.18)

−1.17 (3.42)

0.73

LDL-C (mg/dL), post-medication

96.00 (38.90)

4.95 (5.78)

0.39

LDL-C (mg/dL), pre-medication

105.00 (39.70)

−3.20 (4.26)

0.45

PR Interval (msec) (n = 781)

159.00 (17.92)

−0.12 (4.30)

0.98

QRS duration (msec) (n = 837)

82.00 (8.65)

7.98 (1.99)

6.7x10 -5

QT interval (msec) (n = 783)

376.00 (27.84)

11.62 (6.66)

0.08

Systolic blood pressure (mm Hg), baseline (n = 10,025)

125.00 (22.54)

−1.43 (1.54)

0.35

Systolic blood pressure (mm Hg), post-medication (n = 5,653)

132.00 (16.03)

0.78 (1.43)

0.58

Systolic blood pressure (mm Hg), pre-medication (n = 7,009)

123.00 (16.38)

−0.0003 (1.34)

0.99

Total cholesterol (mg/dL), regardless of medication status (n = 5,439)

175.00 (39.48)

−1.65 (3.70)

0.65

Total cholesterol (mg/dL), post-medication (n = 2,150)

173.50 (44.22)

3.48 (6.58)

0.60

Total cholesterol (mg/dL), pre-medication (n = 4,642)

181.00 (44.86)

−3.57 (4.55)

0.43

Triglycerides (mg/dL), regardless of medication status (n = 5,269)

98.00 (69.46)

3.34 (6.61)

0.61

Triglycerides (mg/dL), post-medication (n = 2,115)

110.00 (74.07)

10.63 (11.07)

0.34

Triglycerides (mg/dL), pre-medication (n = 4,445)

97.00 (79.25)

2.00 (8.20)

0.81

Uric acid (mg/dL) (n = 2,465)

5.40 (2.18)

0.06 (0.29)

0.84

  1. Tests of association were performed using logistic and linear regression between 36 outcomes and percent European global genetic ancestry among African Americans in EAGLE BioVU (n = 11,166). Descriptive statistics as well as summary statistics of all associations are shown for each outcome tested.
  2. Abbreviations: odds ratio (OR), standard deviation (SD), standard error (SE)
  3. Significant associations are bolded and italicized